Research on upper gastrointestinal cancers using tissue and blood samples

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on understanding the biology of upper gastrointestinal cancers, specifically gastric and esophageal cancers. It involves collecting tissue samples and blood from patients diagnosed with these cancers or those at high hereditary risk. The research aims to investigate the roles of genes and proteins in the development of these cancers, providing insights that could lead to better understanding and treatment options.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Over 18
2. Diagnosed with gastric or esophageal cancer OR at an increased hereditary risk for upper GI cancer

Exclusion Criteria:

1. Under 18
2. No family or personal history of gastric or esophageal cancer

Where it's running

• Stanford University School of Medicine
  Stanford, California, United States Recruiting

Study contacts

• Principal investigator: James M Ford — Stanford University
• Study coordinator: Meredith Mills
• Email: bluett@stanford.edu
• Phone: (650) 724-5223

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• IM-1617 in people with advanced solid cancers

  A first-in-human study will test IM-1617 to see if it is safe and helps treat solid tumors that have spread or cannot be removed.

  Recruiting at 5 sites Phase 1 Immunome, Inc. · New Haven, Connecticut and 4 other locations · NCT07578571

• Best time for minimally invasive local treatment after first-line systemic therapy for limited (oligo) esophageal or stomach cancer

  This trial will test whether giving local treatment (surgery or radiation) earlier or later after first-line systemic therapy works better for people whose esophageal or stomach cancer has spread to only a few sites.

  Recruiting at 4 sites Phase 2 Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Amsterdam and 4 other locations · NCT07000253

• Using brodalumab to treat immune-related side effects from cancer therapy

  This study is testing if brodalumab can help cancer patients who are having immune-related side effects from their immunotherapy treatment feel better.

  Recruiting Phase 1 Columbia University · New York, New York · NCT06673329

• Combining TIL Therapy and Pembrolizumab for Advanced Stomach and Esophageal Cancer

  This study is testing a new treatment that combines a type of immune therapy using patients' own tumor cells with a drug called Pembrolizumab to see if it helps people with advanced stomach and esophageal cancer.

  Recruiting Phase 1/2 Essen Biotech · Beijing, Beijing Municipality · NCT06532799

• Improving care for Black patients with gastrointestinal cancer

  This study is trying to improve cancer care for Black patients with gastrointestinal cancers by ensuring they get the right tests and treatments while helping us understand the challenges they face.

  Recruiting Case Comprehensive Cancer Center · Cleveland, Ohio · NCT06263088

• Validation of a blood test for early cancer detection and monitoring

  This study is testing a blood test to see if it can help find different types of cancer early and monitor patients after treatment.

  Recruiting at 3 sites Adela, Inc · Duarte, California and 16 other locations · NCT05366881

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.